Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DermaBind TL in Non-Healing Ulcers
NCT07172893Phase 4Completed
- Sponsor
- Healthtech Wound Care
- Start
- Dec 2025
- Primary completion
- Oct 2026
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of DermaBind TL in diabetic foot ulcer (DFU) and venous leg ulcer (VLU), sponsored by Healthtech Wound Care. Primary endpoint: Protective effect of the wound covering on the wound at 13 weeks. Started Dec 2025; status: completed.
02
Drugs
DermaBind TL
03
Conditions
diabetic foot ulcer (DFU)venous leg ulcer (VLU)
Beyond the preview
Go deeper on NCT07172893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07172893.